News coverage about St Jude Medical (NYSE:STJ) has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. St Jude Medical earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news articles about the medical technology company an impact score of 45.3891135585532 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
NYSE:STJ remained flat at $$80.82 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.93 and a quick ratio of 1.31. St Jude Medical has a 1 year low of $48.83 and a 1 year high of $84.00.
St Jude Medical Company Profile
St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.
Receive News & Ratings for St Jude Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for St Jude Medical and related companies with MarketBeat.com's FREE daily email newsletter.